BRPI0904020B8 - composição vacinal contra o vírus da dengue, e, kit - Google Patents
composição vacinal contra o vírus da dengue, e, kitInfo
- Publication number
- BRPI0904020B8 BRPI0904020B8 BRPI0904020A BRPI0904020A BRPI0904020B8 BR PI0904020 B8 BRPI0904020 B8 BR PI0904020B8 BR PI0904020 A BRPI0904020 A BR PI0904020A BR PI0904020 A BRPI0904020 A BR PI0904020A BR PI0904020 B8 BRPI0904020 B8 BR PI0904020B8
- Authority
- BR
- Brazil
- Prior art keywords
- dengue virus
- dna vaccines
- kit
- vaccine composition
- virus
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108010041986 DNA Vaccines Proteins 0.000 abstract 4
- 229940021995 DNA vaccine Drugs 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 238000010276 construction Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229960001515 yellow fever vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
método, kit, plasmídeo e composição para induzir resposta imune contra vírus da dengue baseado em vacinas de dna e vírus quiméricos. a presente invenção se refere a um método para induzir resposta imune contra vírus da dengue baseado em vacinas de dna e vírus quiméricos 17d em imunizações combinadas ou co- administradas. também estão dentro do escopo da presente invenção, vacinas de dna contra os quatro sorotipos do vírus dengue a partir da construção de diferentes plasmideos recombinantes contendo o gene que codifica a proteína e, ou somente a seqúência que corresponde ao domínio iii desta proteína, a partir de cada sorotipo viral do vírus dengue (denv1-4). a invenção fornece ainda urna composição vacinal consistindo de (a) vacinas de dna contra os quatro sorotípos do vírus dengue, (b) vírus quiméricos compreendendo o vírus vacinal de febre amarela 17d modificado; e (c) um veículo farmaceuticamente aceitável, está incluído no escopo de proteção.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
US13/499,697 US10357558B2 (en) | 2009-10-01 | 2010-08-01 | Method, kit, plasmid and composition for inducing an immune response to dengue virus, on the basis of DNA and chimeric virus vaccines |
EP10819756.7A EP2484376A4 (en) | 2009-10-01 | 2010-08-01 | METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE AGAINST THE DENGUE VIRUS USING DNA VACCINES AND CHIMERIC VIRUSES |
PE2016001214A PE20161094A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
CN201080052438.4A CN102711817B (zh) | 2009-10-01 | 2010-08-01 | 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物 |
PCT/BR2010/000323 WO2011038473A1 (pt) | 2009-10-01 | 2010-08-01 | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos |
PE2012000411A PE20121171A1 (es) | 2009-10-01 | 2010-08-01 | Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos |
CL2012000783A CL2012000783A1 (es) | 2009-10-01 | 2012-03-29 | Proceso para mejorar la eficacia de proteccion metodo para inducir una respuesta inmune contra el virus del dengue que comprende vacunas de dna y virus quimericos 17d; composicion vacunal que comprende vacunas de dna contra los cuatro serotipos del virus dengue y virus quimericos comprendiendo el virus vacunal de fiebre amarilla; plasmido recombinante conteniendo el gen de la proteína e. |
CU20120057A CU24060B1 (es) | 2009-10-01 | 2012-04-02 | Composición vacunal contra el virus del dengue, kit y plásmido |
CO12069004A CO6541529A2 (es) | 2009-10-01 | 2012-04-26 | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos |
ECSP12012131 ECSP12012131A (es) | 2009-10-01 | 2012-05-04 | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quiméricos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0904020A2 BRPI0904020A2 (pt) | 2011-06-14 |
BRPI0904020B1 BRPI0904020B1 (pt) | 2019-11-12 |
BRPI0904020B8 true BRPI0904020B8 (pt) | 2021-05-25 |
Family
ID=43825448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0904020A BRPI0904020B8 (pt) | 2009-10-01 | 2009-10-01 | composição vacinal contra o vírus da dengue, e, kit |
Country Status (10)
Country | Link |
---|---|
US (1) | US10357558B2 (pt) |
EP (1) | EP2484376A4 (pt) |
CN (1) | CN102711817B (pt) |
BR (1) | BRPI0904020B8 (pt) |
CL (1) | CL2012000783A1 (pt) |
CO (1) | CO6541529A2 (pt) |
CU (1) | CU24060B1 (pt) |
EC (1) | ECSP12012131A (pt) |
PE (2) | PE20161094A1 (pt) |
WO (1) | WO2011038473A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3177574A1 (en) * | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
MX366154B (es) | 2013-06-21 | 2019-06-28 | Merck Sharp & Dohme | Composiciones de vacuna del virus del dengue y metodos de uso de las mismas. |
ITRM20130458A1 (it) | 2013-08-05 | 2015-02-05 | Internat Ct For Genetic En Gineering And | Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope |
EP3236997B1 (en) * | 2014-12-22 | 2024-05-29 | Merck Sharp & Dohme LLC | Dengue virus vaccine compositions and methods of use thereof |
US20220226401A1 (en) | 2018-09-05 | 2022-07-21 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
US6962708B1 (en) * | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
BRPI9701774B8 (pt) | 1997-04-11 | 2015-09-29 | Fundação Oswaldo Cruz Fiocruz | cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela. |
US6881723B1 (en) * | 1998-11-05 | 2005-04-19 | Powderject Vaccines, Inc. | Nucleic acid constructs |
WO2003102166A2 (en) * | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
CA2618783A1 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
CN101287490B (zh) * | 2005-08-10 | 2013-04-24 | 阿坎姆比斯公司 | 对抗登革热病毒感染的疫苗接种 |
CU23586A1 (es) * | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
EP2462930B1 (en) * | 2006-11-09 | 2017-05-31 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
KR101686942B1 (ko) * | 2008-01-11 | 2016-12-28 | 이노비오 파마수티컬즈, 인크. | 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신 |
-
2009
- 2009-10-01 BR BRPI0904020A patent/BRPI0904020B8/pt active IP Right Grant
-
2010
- 2010-08-01 WO PCT/BR2010/000323 patent/WO2011038473A1/pt active Application Filing
- 2010-08-01 PE PE2016001214A patent/PE20161094A1/es unknown
- 2010-08-01 US US13/499,697 patent/US10357558B2/en not_active Expired - Fee Related
- 2010-08-01 CN CN201080052438.4A patent/CN102711817B/zh not_active Expired - Fee Related
- 2010-08-01 PE PE2012000411A patent/PE20121171A1/es active IP Right Grant
- 2010-08-01 EP EP10819756.7A patent/EP2484376A4/en not_active Withdrawn
-
2012
- 2012-03-29 CL CL2012000783A patent/CL2012000783A1/es unknown
- 2012-04-02 CU CU20120057A patent/CU24060B1/es active IP Right Grant
- 2012-04-26 CO CO12069004A patent/CO6541529A2/es unknown
- 2012-05-04 EC ECSP12012131 patent/ECSP12012131A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CU24060B1 (es) | 2014-12-26 |
WO2011038473A8 (pt) | 2012-07-19 |
BRPI0904020A2 (pt) | 2011-06-14 |
PE20121171A1 (es) | 2012-08-30 |
CL2012000783A1 (es) | 2013-03-22 |
WO2011038473A1 (pt) | 2011-04-07 |
CN102711817A (zh) | 2012-10-03 |
CO6541529A2 (es) | 2012-10-16 |
ECSP12012131A (es) | 2013-02-28 |
EP2484376A4 (en) | 2014-01-22 |
EP2484376A1 (en) | 2012-08-08 |
PE20161094A1 (es) | 2016-10-22 |
CU20120057A7 (es) | 2013-01-30 |
CN102711817B (zh) | 2016-10-26 |
US20120251570A1 (en) | 2012-10-04 |
US10357558B2 (en) | 2019-07-23 |
BRPI0904020B1 (pt) | 2019-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape | |
Belete | A review on Promising vaccine development progress for COVID-19 disease | |
Belete | Review on up-to-date status of candidate vaccines for COVID-19 disease | |
Li et al. | Rational design of a flavivirus vaccine by abolishing viral RNA 2′-O methylation | |
Sheahan et al. | Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus | |
Okamura et al. | Could live attenuated vaccines better control COVID-19? | |
US10849972B2 (en) | Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus | |
Rahn et al. | Vaccines against influenza A viruses in poultry and swine: Status and future developments | |
Li et al. | A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques | |
BRPI0904020B8 (pt) | composição vacinal contra o vírus da dengue, e, kit | |
BRPI0512421A (pt) | recombinantes de avipox expressando genes do vìrus da doença febre aftosa | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
WO2003072719A3 (en) | Metapneumovirus strains and their use in vaccine formulations and as vector for expression of antigenic sequences | |
WO2004096993A3 (en) | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus | |
CL2012000447A1 (es) | Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica. | |
MX346245B (es) | Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria. | |
WO2010057159A3 (en) | Antigens that elicit immune response against flavivirus and methods of using same | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
Trucchi et al. | Universal influenza virus vaccines: what needs to happen next? | |
JP2017526689A5 (pt) | ||
BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
BRPI0813313A8 (pt) | Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv. | |
Márquez-Escobar | Current developments and prospects on human metapneumovirus vaccines | |
Elkashif et al. | Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B15V | Prolongation of time limit allowed |